On 14th August Glenmark Pharmaceuticals a global research-led pharmaceutical company announced q1fy26 numbers.
Glenmark Pharma Consolidated revenue was flat at Rs 3,264 Cr up 0.6% yoy, however Net Profit declined 86.2% yoy to 47crs form 340crs from q1fy25. However company has exceptional loss of 323.2crs inthis Q1.
EBITDA and Margin fell slightly, EBITDA at Rs580.5crs down(1.4%) yoy, Margin at 17.8% from 18.1%(yoy).
Shares of Glenmark Pharma closed at 2,044.90 INR up 0.77% NSE. Q1 Results Announced after market hours.
Regional Performance:
- India Business growth at 3.7%yoy, 31.8%qoq.
- North America business declined 0.4%yoy, 8.9%QoQ.
- Europe Business declined 4%yoy, 9%QoQ.
- Emerging Markets business grown 0.2%yoy, declined 27.6% QoQ.
- ( Emerging markets includes, Russia + CIS (RCIS), Latin America (LATAM), Middle East and Africa (MEA), Asia-Pacific (APAC) (excluding India)
Business Segment Highlights:
- India Business Outperformed compared to IPM (Indian Pharmaceutical Market) Growth at more than 15%. Launched new Ongology Drugs TEVIMBR (Tislelizumab) and BRUKINSA® (Zanubrutinib) in India.
- Launched 3 products in North America. 52 AND’S pending for approval including 24 para IV applications. Built out a large commercial injectable portfolio through partnerships.
- slowdown in Europe Business during the quarter was offset by branded business growth. Expecting overall region to record double-digit growth in FY26.
- Anticipate double-digitgrowth in FY26 on a constant currency basis in Emerging Markets.
Product & Brand Updates:
- RYALTRIS® have been submitted in more than 90 countries across the world and the producthas been commercialized in >45 markets.(as of june 2025).
- Glenmark’s partner in Mainland China, Grand Pharmaceutical (China) Co. Ltd., expects to receive the approval in FY26.
- Glenmark has filed QiNHAYO in ~15 markets in FY25; the first market launch is expected in FY26.
- The Company has launched WINLEVI® in the UK and is expecting approval in other European markets by end of FY26.
Chairman and Managing Director of Glenmark Pharmaceuticals Ltd Mr. Glenn Saldanha said:
“In Q1FY26, our U.S. business delivered QoQ growth, driven by a combination of injectable and partnered products launches. Our Europe and Emerging markets businesses have recorded >25% CAGR and >10% CAGR respectively over the last three years, and we expect the region to deliver a double-digit growth from the second quarter onwards. The recent IGI-AbbVie global licensing agreement for ISB 2001 is a strong validation of our innovation capabilities. We remain confident in our strategy to drive growth across our markets, while advancing our branded, specialty, and innovative products to deliver long-term value for our stakeholders.“
Disclaimer: The above information is based on company investor presentation /publicly available sources and is not investment advice.